Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial

Detalhes bibliográficos
Autor(a) principal: Rubio, Fernando Góngora
Data de Publicação: 2008
Outros Autores: Cunha, Clóvis Arns da, Lundgren, Fernando Luiz Cavalcanti, Lima, Maria Patelli Juliani Souza, Teixeira, Paulo J. Z, Oliveira, Julio Cesar Abreu de, Golin, Valdir, Mattos, Waldo Luis Leite Dias de, Mählmann, Herbert K, Moreira Junior, Edson Duarte, Jardim, José Roberto, Silva, Rodney L. F, Silva, Patricia H. B
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/19351
Resumo: Edson Duarte Moreira Junior “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.
id CRUZ_102483694d6e6190746eb504013ef240
oai_identifier_str oai:www.arca.fiocruz.br:icict/19351
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Rubio, Fernando GóngoraCunha, Clóvis Arns daLundgren, Fernando Luiz CavalcantiLima, Maria Patelli Juliani SouzaTeixeira, Paulo J. ZOliveira, Julio Cesar Abreu deGolin, ValdirMattos, Waldo Luis Leite Dias deMählmann, Herbert KMoreira Junior, Edson DuarteJardim, José RobertoSilva, Rodney L. FSilva, Patricia H. B2017-06-08T16:41:32Z2017-06-08T16:41:32Z2008RUBIO, F. G. et al. Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial. Brazilian Journal of Infectious Diseases, v. 12, n. 3, p. 202-209, 208.1413-8670https://www.arca.fiocruz.br/handle/icict/19351Edson Duarte Moreira Junior “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.Hospital de Base of FUNFARME. São José do Rio Preto, SP, BrasilNossa Senhora das Graças Hospital. Curitiba, PR, BrasilOtávio de Freitas General Hospital. Recife, PE, BrasilCatholic University of Campinas, Campus II. Department of Infectious Diseases. Campinas, SP, BrasilIrmandade da Santa Casa de Misericórdia of Porto Alegre. Porto Alegre, RS, BrasilUniversity Hospital of Federal University of Juiz de Fora. Juiz de Fora, MG, BrasilIrmandade da Santa Casa de Misericórdia of São Paulo. São Paulo, SP, BrasilNossa Senhora da Conceição Hospital. Porto Alegre, RS, BrasilGeneral Hospital of Itapecerica da Serra. OSS Seconci. Itapecerica da Serra, SP, BrasilGeneral Hospital Roberto Santos. Salvador, BA, BrasilFederal University of São Paulo. São Paulo, SP, BrasilFederal University of Paraná. Clinical Hospital de Clinicas. Curitiba, PR, BrasilSanatorinhos Hospital. OSS. Ação Comunitária. São Paulo, SP, BrasilCommunity-Acquired Pneumonia (CAP) is a major public health problem. In Brazil it has been estimated that 2,000,000 people are affected by CAP every year. Of those, 780,000 are admitted to hospital, and 30,000 have death as the outcome. This is an open-label, non-comparative study with the purpose of evaluating efficacy, safety, and tolerability levels of IV azithromycin (IVA) and IV ceftriaxone (IVC), followed by oral azithromycin (OA) for the treatment of inpatients with mild to severe CAP. Eighty-six patients (mean age 56.6 ± 19.8) were administered IVA (500mg/day) and IVC (1g/day) for 2 to 5 days, followed by AO (500mg/day) to complete a total of 10 days. At the end of treatment (EOT) and after 30 days (End of Study - EOS) the medication was evaluated clinically, microbiologically and for tolerability levels. Out of the total 86-patient population, 62 (72.1%) completed the study. At the end of treatment, 95.2% (CI95: 88.9% – 100%) reported cure or clinical improvement; at the end of the study, that figure was 88.9% (CI95: 74.1% – 91.7%). Out of the 86 patients enrolled in the study, 15 were microbiologically evaluable for bacteriological response. Of those, 6 reported pathogen eradication at the end of therapy (40%), and 8 reported presumed eradication (53.3%). At end of study evaluation, 9 patients showed pathogen eradication (50%), and 7 showed presumed eradication (38.89%). Therefore, negative cultures were obtained from 93.3% of the patients at EOT, and from 88.9% at the end of the study. One patient (6.67% of patient population) reported presumed microbiological resistance. At study end, 2 patients (11.11%) still reported undetermined culture. Uncontrollable vomiting and worsening pneumonia condition were reported by 2.3% of patients. Discussion and Conclusion Treatment based on the administration of IV azithromycin associated to ceftriaxone and followed by oral azithromycin proved to be efficacious and well-tolerated in the treatment of Brazilian inpatients with CAP.engElsevierInfecções comunitárias adquiridasPneumoniaAntigenos bacterianosAzitromicinaCommunity acquired infectionsPneumoniaAnti-bacterial agentsMacrolide ketolidesAzithromycinInfecções comunitárias adquiridasPneumoniaAntigenos bacterianosAzitromicinaIntravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/19351/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALRubio FG intraveneous azithromycin plus....pdfRubio FG intraveneous azithromycin plus....pdfapplication/pdf56192https://www.arca.fiocruz.br/bitstream/icict/19351/2/Rubio%20FG%20intraveneous%20azithromycin%20plus....pdf1e7e5951a977bf7d633fed5b19995e47MD52TEXTRubio FG intraveneous azithromycin plus....pdf.txtRubio FG intraveneous azithromycin plus....pdf.txtExtracted texttext/plain43020https://www.arca.fiocruz.br/bitstream/icict/19351/3/Rubio%20FG%20intraveneous%20azithromycin%20plus....pdf.txt7db29f74ce73466ed020afc765aa0384MD53icict/193512023-03-15 14:34:08.522oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:08Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial
title Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial
spellingShingle Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial
Rubio, Fernando Góngora
Infecções comunitárias adquiridas
Pneumonia
Antigenos bacterianos
Azitromicina
Community acquired infections
Pneumonia
Anti-bacterial agents
Macrolide ketolides
Azithromycin
Infecções comunitárias adquiridas
Pneumonia
Antigenos bacterianos
Azitromicina
title_short Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial
title_full Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial
title_fullStr Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial
title_full_unstemmed Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial
title_sort Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial
author Rubio, Fernando Góngora
author_facet Rubio, Fernando Góngora
Cunha, Clóvis Arns da
Lundgren, Fernando Luiz Cavalcanti
Lima, Maria Patelli Juliani Souza
Teixeira, Paulo J. Z
Oliveira, Julio Cesar Abreu de
Golin, Valdir
Mattos, Waldo Luis Leite Dias de
Mählmann, Herbert K
Moreira Junior, Edson Duarte
Jardim, José Roberto
Silva, Rodney L. F
Silva, Patricia H. B
author_role author
author2 Cunha, Clóvis Arns da
Lundgren, Fernando Luiz Cavalcanti
Lima, Maria Patelli Juliani Souza
Teixeira, Paulo J. Z
Oliveira, Julio Cesar Abreu de
Golin, Valdir
Mattos, Waldo Luis Leite Dias de
Mählmann, Herbert K
Moreira Junior, Edson Duarte
Jardim, José Roberto
Silva, Rodney L. F
Silva, Patricia H. B
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Rubio, Fernando Góngora
Cunha, Clóvis Arns da
Lundgren, Fernando Luiz Cavalcanti
Lima, Maria Patelli Juliani Souza
Teixeira, Paulo J. Z
Oliveira, Julio Cesar Abreu de
Golin, Valdir
Mattos, Waldo Luis Leite Dias de
Mählmann, Herbert K
Moreira Junior, Edson Duarte
Jardim, José Roberto
Silva, Rodney L. F
Silva, Patricia H. B
dc.subject.other.pt_BR.fl_str_mv Infecções comunitárias adquiridas
Pneumonia
Antigenos bacterianos
Azitromicina
topic Infecções comunitárias adquiridas
Pneumonia
Antigenos bacterianos
Azitromicina
Community acquired infections
Pneumonia
Anti-bacterial agents
Macrolide ketolides
Azithromycin
Infecções comunitárias adquiridas
Pneumonia
Antigenos bacterianos
Azitromicina
dc.subject.en.pt_BR.fl_str_mv Community acquired infections
Pneumonia
Anti-bacterial agents
Macrolide ketolides
Azithromycin
dc.subject.decs.pt_BR.fl_str_mv Infecções comunitárias adquiridas
Pneumonia
Antigenos bacterianos
Azitromicina
description Edson Duarte Moreira Junior “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.
publishDate 2008
dc.date.issued.fl_str_mv 2008
dc.date.accessioned.fl_str_mv 2017-06-08T16:41:32Z
dc.date.available.fl_str_mv 2017-06-08T16:41:32Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv RUBIO, F. G. et al. Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial. Brazilian Journal of Infectious Diseases, v. 12, n. 3, p. 202-209, 208.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/19351
dc.identifier.issn.pt_BR.fl_str_mv 1413-8670
identifier_str_mv RUBIO, F. G. et al. Intravenous Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of Inpatients With Community-Acquired Pneumonia: An Open-Label, Non-Comparative Multicenter Trial. Brazilian Journal of Infectious Diseases, v. 12, n. 3, p. 202-209, 208.
1413-8670
url https://www.arca.fiocruz.br/handle/icict/19351
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/19351/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/19351/2/Rubio%20FG%20intraveneous%20azithromycin%20plus....pdf
https://www.arca.fiocruz.br/bitstream/icict/19351/3/Rubio%20FG%20intraveneous%20azithromycin%20plus....pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
1e7e5951a977bf7d633fed5b19995e47
7db29f74ce73466ed020afc765aa0384
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324699325792256

Registros relacionados